Council of Scientific and Industrial Research (CSIR), Lucknow-based constituent laboratory Central Drug Research Institute (CDRI) and Marc Laboratories Ltd, India, have developed a brand new, safer drug for heart attack and stroke. In addition, they’ve signed the MoU for developing a cure for coronary and cerebral artery diseases.

Marc Laboratories is an Uttar Pradesh-based young progressive enterprise with an operational base in 13 additional states. This agreement between CSIR-CDRI and Marc Laboratories could pave the way for developing a synthetic compound S-007-867 because it modulates blood coagulation cascade, specifically as an inhibitor of collagen-induced platelet aggregation. As a result, it might assist in treating cerebral and coronary artery diseases, the CSIR-CDRI statement stated.

Arterial thrombosis is a severe complication that develops on the chronic lesions of atherosclerosis resulting in heart attack and stroke. Thus, platelet−collagen interaction inhibition is likely to become a promising therapeutic approach to deal with intravascular thrombosis. The compound, S-007-867, considerably inhibits collagen-mediated platelet stimulation and subsequently reduces ATP release from dense granules and thromboxane A2 through COX1 activation. As a result, it effectively maintains blood flow, delays blockage of the blood vessel, and inhibits blood clot formation without undermining hemostasis.

This medication has a minor threat as compared to existing remedies for cerebral and coronary artery diseases. Furthermore, in animal experiments, the chemical exerts better antithrombotic protection than the standard of maintenance with minimal bleeding. The institute has just obtained permission to commence Phase-I clinical trials for this drug.

In the case of COVID-19, crucial patients with acute respiratory distress syndrome (ARDS) have elevated D-dimer and decreased prothrombin time (PT), indicating a pro-thrombotic state. Additionally, those patients have a high number of circulating neutrophils, inflammatory mediators/cytokine, CRP and lymphocytopenia. Therefore, drugs decreasing platelet reactivity and neutrophil activation might be advantageous.

Prof. Tapas K. Kundu, Director (CDRI), stated that this is an excellent time for CSIR-CDRI to permit out an in-house designed chemical for additional investigations as part of our dedication of affordable health care for everybody.” He was hopeful that this chemical would get to the industry shortly to benefit mankind.

This venture will undoubtedly be very beneficial for the growth of the pharma industry in Uttar Pradesh and will open up new paths. The JV has the approval of the Union Minister for Health & Family Welfare, Dr Harsh Vardhan, the Director General of CSIR, Dr Shekhar C. Mande, and UP CM Sri. Yogi Adityanath.